TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

Pavla Brachova, Samuel R. Mueting, Matthew J. Carlson, Michael J. Goodheart, Anna M. Button, Sarah L. Mott, Donghai Dai, Kristina W. Thiel, Eric J. Devor, Kimberly K. Leslie

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term 'oncomorphic'. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determine the relationship of oncomorphic TP53 mutations with patient outcomes in advanced serous ovarian cancer patients. Clinical and molecular data from 264 high-grade serous ovarian cancer patients uniformly treated with standard platinum-.and taxane-based adjuvant chemotherapy were downloaded from The Cancer Genome Atlas (TCGA ) portal. Additionally, patient samples were obtained from the University of Iowa and individual mutations were analyzed in ovarian cancer cell lines. Mutations in the TP53 were annotated and categorized as oncomorphic, loss of function (LOF ), or unclassified. Associations between mutation types, chemoresistance, recurrence, and progression-free survival (PFS) were calculated. Oncomorphic TP53 mutations were present in 21.3% of ovarian cancers in the TCGA dataset. Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60% higher risk of recurrence (HR=1.60, 95% confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (?2 test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic. Furthermore, tumors containing oncomorphic TP53 mutations displayed unique protein expression profiles, and some mutations conferred increased clonogenic capacity in ovarian cancer cell models. Our study reveals that oncomorphic TP53 mutations are associated with worse patient outcome. These data suggest that future studies should take into consideration the functional consequences of TP53 mutations when determining treatment options.

Original languageEnglish (US)
Pages (from-to)607-618
Number of pages12
JournalInternational Journal of Oncology
Volume46
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Platinum
Carcinoma
Drug Therapy
Mutation
Ovarian Neoplasms
Atlases
Neoplasms
taxane
Disease-Free Survival
Genome
Recurrence
Proteins
Adjuvant Chemotherapy
Nucleotides

Keywords

  • Chemoresistance
  • Gain-of-function
  • Oncomorphic p53 mutation
  • Ovarian cancer
  • TP53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. / Brachova, Pavla; Mueting, Samuel R.; Carlson, Matthew J.; Goodheart, Michael J.; Button, Anna M.; Mott, Sarah L.; Dai, Donghai; Thiel, Kristina W.; Devor, Eric J.; Leslie, Kimberly K.

In: International Journal of Oncology, Vol. 46, No. 2, 01.02.2015, p. 607-618.

Research output: Contribution to journalArticle

Brachova, Pavla ; Mueting, Samuel R. ; Carlson, Matthew J. ; Goodheart, Michael J. ; Button, Anna M. ; Mott, Sarah L. ; Dai, Donghai ; Thiel, Kristina W. ; Devor, Eric J. ; Leslie, Kimberly K. / TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. In: International Journal of Oncology. 2015 ; Vol. 46, No. 2. pp. 607-618.
@article{e445368e51074e6a82c7365d14e68e08,
title = "TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma",
abstract = "Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term 'oncomorphic'. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determine the relationship of oncomorphic TP53 mutations with patient outcomes in advanced serous ovarian cancer patients. Clinical and molecular data from 264 high-grade serous ovarian cancer patients uniformly treated with standard platinum-.and taxane-based adjuvant chemotherapy were downloaded from The Cancer Genome Atlas (TCGA ) portal. Additionally, patient samples were obtained from the University of Iowa and individual mutations were analyzed in ovarian cancer cell lines. Mutations in the TP53 were annotated and categorized as oncomorphic, loss of function (LOF ), or unclassified. Associations between mutation types, chemoresistance, recurrence, and progression-free survival (PFS) were calculated. Oncomorphic TP53 mutations were present in 21.3{\%} of ovarian cancers in the TCGA dataset. Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60{\%} higher risk of recurrence (HR=1.60, 95{\%} confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (?2 test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic. Furthermore, tumors containing oncomorphic TP53 mutations displayed unique protein expression profiles, and some mutations conferred increased clonogenic capacity in ovarian cancer cell models. Our study reveals that oncomorphic TP53 mutations are associated with worse patient outcome. These data suggest that future studies should take into consideration the functional consequences of TP53 mutations when determining treatment options.",
keywords = "Chemoresistance, Gain-of-function, Oncomorphic p53 mutation, Ovarian cancer, TP53",
author = "Pavla Brachova and Mueting, {Samuel R.} and Carlson, {Matthew J.} and Goodheart, {Michael J.} and Button, {Anna M.} and Mott, {Sarah L.} and Donghai Dai and Thiel, {Kristina W.} and Devor, {Eric J.} and Leslie, {Kimberly K.}",
year = "2015",
month = "2",
day = "1",
doi = "10.3892/ijo.2014.2747",
language = "English (US)",
volume = "46",
pages = "607--618",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

AU - Brachova, Pavla

AU - Mueting, Samuel R.

AU - Carlson, Matthew J.

AU - Goodheart, Michael J.

AU - Button, Anna M.

AU - Mott, Sarah L.

AU - Dai, Donghai

AU - Thiel, Kristina W.

AU - Devor, Eric J.

AU - Leslie, Kimberly K.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term 'oncomorphic'. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determine the relationship of oncomorphic TP53 mutations with patient outcomes in advanced serous ovarian cancer patients. Clinical and molecular data from 264 high-grade serous ovarian cancer patients uniformly treated with standard platinum-.and taxane-based adjuvant chemotherapy were downloaded from The Cancer Genome Atlas (TCGA ) portal. Additionally, patient samples were obtained from the University of Iowa and individual mutations were analyzed in ovarian cancer cell lines. Mutations in the TP53 were annotated and categorized as oncomorphic, loss of function (LOF ), or unclassified. Associations between mutation types, chemoresistance, recurrence, and progression-free survival (PFS) were calculated. Oncomorphic TP53 mutations were present in 21.3% of ovarian cancers in the TCGA dataset. Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60% higher risk of recurrence (HR=1.60, 95% confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (?2 test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic. Furthermore, tumors containing oncomorphic TP53 mutations displayed unique protein expression profiles, and some mutations conferred increased clonogenic capacity in ovarian cancer cell models. Our study reveals that oncomorphic TP53 mutations are associated with worse patient outcome. These data suggest that future studies should take into consideration the functional consequences of TP53 mutations when determining treatment options.

AB - Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term 'oncomorphic'. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determine the relationship of oncomorphic TP53 mutations with patient outcomes in advanced serous ovarian cancer patients. Clinical and molecular data from 264 high-grade serous ovarian cancer patients uniformly treated with standard platinum-.and taxane-based adjuvant chemotherapy were downloaded from The Cancer Genome Atlas (TCGA ) portal. Additionally, patient samples were obtained from the University of Iowa and individual mutations were analyzed in ovarian cancer cell lines. Mutations in the TP53 were annotated and categorized as oncomorphic, loss of function (LOF ), or unclassified. Associations between mutation types, chemoresistance, recurrence, and progression-free survival (PFS) were calculated. Oncomorphic TP53 mutations were present in 21.3% of ovarian cancers in the TCGA dataset. Patients with oncomorphic TP53 mutations demonstrated significantly worse PFS, a 60% higher risk of recurrence (HR=1.60, 95% confidence intervals 1.09, 2.33, p=0.015), and higher rates of platinum resistance (?2 test p=0.0024) when compared with single nucleotide mutations not categorized as oncomorphic. Furthermore, tumors containing oncomorphic TP53 mutations displayed unique protein expression profiles, and some mutations conferred increased clonogenic capacity in ovarian cancer cell models. Our study reveals that oncomorphic TP53 mutations are associated with worse patient outcome. These data suggest that future studies should take into consideration the functional consequences of TP53 mutations when determining treatment options.

KW - Chemoresistance

KW - Gain-of-function

KW - Oncomorphic p53 mutation

KW - Ovarian cancer

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84918502971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918502971&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2747

DO - 10.3892/ijo.2014.2747

M3 - Article

VL - 46

SP - 607

EP - 618

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -